Details

Autor(en) / Beteiligte

• Reiss, Allison B.
• Glass, Daniel S.
• Lam, Eric
• Glass, Amy D.
• De Leon, Joshua
• Kasselman, Lora J.

Titel

Oxytocin: Potential to mitigate cardiovascular risk

Ist Teil von

• Peptides (New York, N.Y. : 1980), 2019-07, Vol.117, p.170089, Article 170089

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2019

Link zum Volltext

Quelle

Elsevier ScienceDirect Journals

Beschreibungen/Notizen

• •Oxytocin may be a candidate treatment for cardiovascular disease.•Oxytocin has effects beyond the reproductive system.•Atheroprotection by oxytocin occurs through multiple actions.•Oxytocin favorably affects weight, glucose handling and blood pressure.•Oxytocin acts through receptors on endothelium, smooth muscle and macrophages. Cardiovascular disease (CVD) remains the leading cause of death worldwide, despite multiple treatment options. In addition to elevated lipid levels, oxidative stress and inflammation are key factors driving atherogenesis and CVD. New strategies are required to mitigate risk and most urgently for statin-intolerant patients. The neuropeptide hormone oxytocin, synthesized in the brain hypothalamus, is worthy of consideration as a CVD ancillary treatment because it moderates factors directly linked to atherosclerotic CVD such as inflammation, weight gain, food intake and insulin resistance. Though initially studied for its contribution to parturition and lactation, oxytocin participates in social attachment and bonding, associative learning, memory and stress responses. Oxytocin has shown promise in animal models of atherosclerosis and in some human studies as well. A number of properties of oxytocin make it a candidate CVD treatment. Oxytocin not only lowers fat mass and cytokine levels, but also improves glucose tolerance, lowers blood pressure and relieves anxiety. Further, it has an important role in communication in the gut-brain axis that makes it a promising treatment for obesity and type 2 diabetes. Oxytocin acts through its receptor which is a class I G-protein-coupled receptor present in cells of the vascular system including the heart and arteries. While oxytocin is not used for heart disease at present, residual CVD risk remains in a substantial portion of patients despite multidrug regimens, leaving open the possibility of using the endogenous nonapeptide as an adjunct therapy. This review discusses the possible role for oxytocin in human CVD prevention and treatment.